Avrupa Birliği - Litvanyaca - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - imunosupresantai - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 ir 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 ir 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Avrupa Birliği - Litvanyaca - EMA (European Medicines Agency)

advicenne s.a. - potassium citrate monohydrated, potassium hydrogen carbonate - acidosis, renal tubular - mineral supplements - sibnayal is indicated for the treatment of distal renal tubular acidosis (drta) in adults, adolescents and children aged one year and older.

Avrupa Birliği - Litvanyaca - EMA (European Medicines Agency)

gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - lytiniai hormonai ir moduliatoriai lytinių organų sistemos, - oral contraceptive.

Avrupa Birliği - Litvanyaca - EMA (European Medicines Agency)

estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - lytiniai hormonai ir moduliatoriai lytinių organų sistemos, - geriamoji kontracepcija. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.

Avrupa Birliği - Litvanyaca - EMA (European Medicines Agency)

merck europe b.v. - tepotinib hydrochloride monohydrate - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Litvanya - Litvanyaca - SMCA (Valstybinė vaistų kontrolės tarnyba)

us pharmacia sp. z o.o. - ibuprofenas/fenilefrino hidrochloridas - dengtos tabletės - 200 mg/6,1 mg - ibuprofen, combinations

Litvanya - Litvanyaca - SMCA (Valstybinė vaistų kontrolės tarnyba)

vioser s.a. parenteral solutions industry - metronidazolas - infuzinis tirpalas - 500 mg/100 ml - metronidazole

Litvanya - Litvanyaca - SMCA (Valstybinė vaistų kontrolės tarnyba)

stada arzneimittel ag - losartano kalio druska - plėvele dengtos tabletės - 100 mg - losartan

Litvanya - Litvanyaca - SMCA (Valstybinė vaistų kontrolės tarnyba)

accord healthcare b.v. - betahistino dihidrochloridas - tabletės - 24 mg - betahistine

Litvanya - Litvanyaca - SMCA (Valstybinė vaistų kontrolės tarnyba)

fresenius kabi polska sp.z.o.o. - alaninas/argininas/asparto rūgštis/acetilcisteinas/glutamo rūgštis/glicinas/histidinas/izoleucinas/leucinas/lizinas, monohidratas/metioninas/fenilalaninas/prolinas/serinas/taurinas/treoninas/triptofanas/tirozinas/valinas/dikalio fosfatas/gliukozė, monohidratas/kalcio gliukonatas monohidratas/magnio laktatas, dihidratas/natrio chloridas/kalio chloridas/cinko acetatas dihidratas/vario sulfatas pentahidratas/natrio fluoridas/seleno dioksidas/mangano chloridas tetrahidratas/kalio jodidas/chromo chloridas heksahidratas/geležies sulfatas heptahidratas/kobalto chloridas heksahidratas/amonio molibdatas tetrahidratas - infuzinis tirpalas - 1,45 g/0,94 g/0,94 g/0,31 g/1,63 g/0,48 g/0,48 g/0,71 g/1,61 g/1,45 g/0,3 g/0,62 g/1,29 g/0,87 g/0,07 g/0,83 g/0,32 g/0,11 g/0,83 g/1,39 g/165 g/2,69 g/0,95 g/1,75 g/0,67 g/6,72 mg/1,18 mg/1,11 mg/0,07 mg/0,36 mg/0,07 mg/0,1 mg/2,49 mg/0,61 mg/0,09 mg/1000 ml; 1,45 g/0,94 g/0,94 g/0,31 g/1,63 g/0,48 g/0,48 g/0,71 g/1,61 g/1,45 g/0,3 g/0,62 g/1,29 g/0,87 g/0,07 g/0,83 g/0,32 g/0,11 g/0,8 - combinations